Abeona Therapeutics (ABEO) vs EyePoint (EYPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed EyePoint (EYPT) over the past year, losing 3.2% versus a loss of 74.9%. Over five years, EYPT leads with a -71.0% price change compared with -77.7% for ABEO. EyePoint is the larger company by market cap ($287.2 million vs $286.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | EYPT |
|---|---|---|
| Share price | $5.01 | $3.43 |
| Market cap | $286.49M | $287.16M |
| 1-day change | -1.38% | +3.16% |
| YTD return | -3.61% | -81.83% |
| 1-year return | -3.24% | -74.94% |
| 5-year return | -77.67% | -70.98% |
| EPS (TTM) | $-1.18 | $-3.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $19.11 |
| 52-week low | $4.00 | $3.05 |
| Distance from 52-week high | -34.51% | -82.08% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +276.85% | +656.50% |
| Average volume | 1.41M | 3.93M |
| Shares outstanding | 57.18M | 83.84M |
| Employees | 226 | 214 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed EYPT by 71.7 percentage points over the past year.
- The two companies sit in different sectors: Abeona Therapeutics in Health Care and EyePoint in Industrials.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
ABEO vs EYPT FAQ
Which is bigger, Abeona Therapeutics or EyePoint?
EyePoint (EYPT) is larger, with a market capitalization of $287.16M compared with $286.49M for Abeona Therapeutics (ABEO).
Which stock has performed better over the past year, ABEO or EYPT?
ABEO returned -3.24% over the past 12 months, compared with -74.94% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and EyePoint in the same industry?
No. Abeona Therapeutics is in the Health Care sector, while EyePoint is in Industrials.